Business
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions.
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions.","length":423,"tagName":"p"},{"type":"image","alt":"BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)","displaySize":"","headline":null,"caption":"BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":59,"url":"https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KxRqzB62ez2RdMQaPUuMVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2","width":400,"height":59}},"href":"https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Therapeutics, Inc. ("Amicus"), it completed the syndication of a new $2 billion senior secured term loan "B" facility (the "Term Loan B Facility"), which Term Loan B Facility is in addition to a $800 million senior secured term loan "A" facility (the "Term Loan A Facility" and, together with the Term Loan B Facility, the "Term Facilities"), and a $600 million senior secured revolving credit facility into which BioMarin expects to enter in connection with the Acquisition (the "New Revolving Facility" and, together with the Term Facilities, the "New Senior Secured Credit Facilities").","length":782,"tagName":"p"},{"type":"text","content":"BioMarin intends to use the net proceeds from the offering of the Notes, together with borrowings under the Term Facilities and cash on hand, to fund the consideration payable in connection with the Acquisition and related fees and expenses in connection with the Acquisition, the borrowings under the New Senior Secur...